Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Butov, Dmitry A, Pashkov, Yuri N, Stepanenko, Anna L, Choporova, Aleksandra I, Butova, Tanya S, Batdelger, Dendev, Jirathitikal, Vichai, Bourinbaiar, Aldar S, Zaitzeva, Svetlana I
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031205/
https://www.ncbi.nlm.nih.gov/pubmed/21244690
http://dx.doi.org/10.1186/1476-8518-9-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031205/
https://www.ncbi.nlm.nih.gov/pubmed/21244690
http://dx.doi.org/10.1186/1476-8518-9-3

Ejemplares similares